Monotherapy of immune checkpoint inhibitors in advanced lines demonstrated a higher objective response rate (26%) in KRAS-mutant patients when compared with other oncogene-driven NSCLC patients (BRAF, ROS1, MET, EGFR, HER2, RET, ALK) as reported in immunotarget study [140]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.